Skip to main content

Table 1 Patients’ characteristics at the time of transplant in the study (n = 93) and lung transplant recipients with/without PRA (n = 23 vs 70, respectively)

From: The fraction of sensitization among lung transplant recipients in a transplant center in Japan

  Total (n = 93) PRA+ (n = 23) PRA- (n = 70) p-value
Age at LTX, median (IQR) 42 (32–50) 45 (33–50) 41 (31–49) 0.423
Sex, female 53 (57.0%) 13 (56.5%) 40 (75.5%) 1.000
LTX procedure
Single 48 (51.6%) 11 (47.8%) 37 (52.9%) 0.935
Double 37 (39.8%) 10 (43.5%) 27 (38.6%)  
Living-donor 8 (8.6%) 2 (8.7%) 6 (8.6%)  
LTX indication
Pulmonary vascular disease 21 (22.6%) 4 (17.4%) 17 (24.3%) 0.282
Restrictive lung disease 19 (20.4%) 7 (30.4%) 12 (17.1%)  
Obstructive lung disease 39 (41.9%) 7 (30.4%) 32 (45.7%)  
Suppurative lung disease 8 (8.6%) 4 (17.4%) 4 (5.7%)  
CLAD 2 (2.2%) 0 (0%) 2 (2.9%)  
Others 4 (4.3%) 1 (4.3%) 3 (4.3%)  
Pre-LTX comorbidities
Diabetes 6 (6.5%) 1 (4.3%) 5 (7.1%) 1.000
Connective tissue disease 14 (15.1%) 6 (23.1%) 8 (11.4%) 0.102
GERD 5 (12.8%) 2 (8.7%) 3 (4.3%) 0.594
Chronic kidney diseasea 3 (3.3%) 1 (4.3%) 2 (2.9%) 1.000
  1. Abbreviation: PRA panel-reactive assay, IQR Interquartile range, LTX lung transplant, CLAD chronic lung allograft dysfunction, GERD gastroesophageal reflux disease
  2. aincalculable the glomerular filtration rate in 2 recipients (n = 91)